Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant

Nilotinib, a BCR‐ABL tyrosine kinase inhibitor, is a known inhibitor of CYP3A4 and could increase the concentration of drugs metabolized by CYP3A4. An immunosuppressive drug for nilotinib‐treated patients following transplant should be administered with careful pharmacokinetic monitoring because of...

Descripción completa

Detalles Bibliográficos
Autores principales: Onaka, Takashi, Takahashi, Naoto, Miura, Masatomo, Yonezawa, Akihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412900/
https://www.ncbi.nlm.nih.gov/pubmed/28469859
http://dx.doi.org/10.1002/ccr3.900
_version_ 1783233098102603776
author Onaka, Takashi
Takahashi, Naoto
Miura, Masatomo
Yonezawa, Akihito
author_facet Onaka, Takashi
Takahashi, Naoto
Miura, Masatomo
Yonezawa, Akihito
author_sort Onaka, Takashi
collection PubMed
description Nilotinib, a BCR‐ABL tyrosine kinase inhibitor, is a known inhibitor of CYP3A4 and could increase the concentration of drugs metabolized by CYP3A4. An immunosuppressive drug for nilotinib‐treated patients following transplant should be administered with careful pharmacokinetic monitoring because of its interaction with nilotinib.
format Online
Article
Text
id pubmed-5412900
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54129002017-05-03 Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant Onaka, Takashi Takahashi, Naoto Miura, Masatomo Yonezawa, Akihito Clin Case Rep Case Reports Nilotinib, a BCR‐ABL tyrosine kinase inhibitor, is a known inhibitor of CYP3A4 and could increase the concentration of drugs metabolized by CYP3A4. An immunosuppressive drug for nilotinib‐treated patients following transplant should be administered with careful pharmacokinetic monitoring because of its interaction with nilotinib. John Wiley and Sons Inc. 2017-03-17 /pmc/articles/PMC5412900/ /pubmed/28469859 http://dx.doi.org/10.1002/ccr3.900 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Onaka, Takashi
Takahashi, Naoto
Miura, Masatomo
Yonezawa, Akihito
Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
title Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
title_full Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
title_fullStr Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
title_full_unstemmed Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
title_short Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
title_sort drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412900/
https://www.ncbi.nlm.nih.gov/pubmed/28469859
http://dx.doi.org/10.1002/ccr3.900
work_keys_str_mv AT onakatakashi druginteractionbetweentacrolimusandnilotinibinapatientwithchronicmyeloidleukemiaafterrenaltransplant
AT takahashinaoto druginteractionbetweentacrolimusandnilotinibinapatientwithchronicmyeloidleukemiaafterrenaltransplant
AT miuramasatomo druginteractionbetweentacrolimusandnilotinibinapatientwithchronicmyeloidleukemiaafterrenaltransplant
AT yonezawaakihito druginteractionbetweentacrolimusandnilotinibinapatientwithchronicmyeloidleukemiaafterrenaltransplant

Ejemplares similares